spironolactone has been researched along with DDD MPGNII in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study was conducted to examine whether spironolactone, a mineralocorticoid receptor antagonist, alone or in combination with cilazapril, an angiotensin converting enzyme (ACE) inhibitor, ameliorates proteinuria and renal lesions in an immune-initiated progressive nephritis model." | 7.72 | Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. ( Asai, M; Fukuda, S; Hayashi, M; Kawachi, H; Marumo, T; Monkawa, T; Saruta, T; Shimizu, F; Tsuji, M; Yoshino, J, 2004) |
| " The present study was conducted to examine whether spironolactone, a mineralocorticoid receptor antagonist, alone or in combination with cilazapril, an angiotensin converting enzyme (ACE) inhibitor, ameliorates proteinuria and renal lesions in an immune-initiated progressive nephritis model." | 3.72 | Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. ( Asai, M; Fukuda, S; Hayashi, M; Kawachi, H; Marumo, T; Monkawa, T; Saruta, T; Shimizu, F; Tsuji, M; Yoshino, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yonemura, K | 1 |
| Yasuda, H | 1 |
| Hishida, A | 1 |
| Asai, M | 1 |
| Monkawa, T | 1 |
| Marumo, T | 1 |
| Fukuda, S | 1 |
| Tsuji, M | 1 |
| Yoshino, J | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Gullulu, M | 1 |
| Akdag, I | 1 |
| Kahvecioglu, S | 1 |
| Filiz, G | 1 |
| Savci, V | 1 |
3 other studies available for spironolactone and DDD MPGNII
| Article | Year |
|---|---|
Distinct responses of membranoproliferative glomerulonephritis-related proteinuria to spironolactone with and without angiotensin II blockade.
Topics: Angiotensin II; Diuretics; Glomerulonephritis, Membranoproliferative; Humans; Proteinuria; Spironola | 2003 |
Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies, Monoclonal; Blood Pressure; Cilazapri | 2004 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Prolife | 2006 |